Healthcare careers for chemists are once again largely based in laboratories, although increasingly there is opportunity to work at the point of care, helping with patient investigation. In a patent, 2682-49-7, name is Thiazolidin-2-one, introducing its new discovery. Synthetic Route of 2682-49-7
A novel tricyclic thiazepine derivative, 6-(p-tolyl)benzo[f] pyrido[2,3-b][1,4] thiazepine 11,11-dioxide (TBPT), exhibits potent inhibitory effects in two non-small-cell lung cancer cell lines, H460 and its drug-resistant variant, H460TaxR, while exhibiting much less toxic effects on normal human fibroblasts. After five injections of TBPT at a dose of 60 mg/kg, it inhibits H460TaxR tumor growth in xenografted mouse models by 66.7% without causing observable toxicity to normal tissues. Based on gene perturbation data and a series of investigations, we reveal that TBPT is not a P-glycoprotein substrate and it inhibits microtubule formation by targeting tubulin, thereby causing cell cycle arrest at the G2/M stage and eventually inducing apoptosis. This redeployment of antidepressant compound scaffold for anticancer applications provides a promising future for conquering drug-resistant tumors with fewer side effects.
This is the end of this tutorial post, and I hope it has helped your research about 2682-49-7. Synthetic Route of 2682-49-7
Reference：
Quinuclidine – Wikipedia,
Quinuclidine | C7H389N | ChemSpider